MedTrace Logo

A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)

NCT00257452 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2013-11-01

No results posted yet for this study

Summary

To demonstrate that tiotropium (Spiriva®) does not prolong the QT interval of the ECG more than placebo

Conditions

  • Healthy

Interventions

DRUG

tiotropium 18 mcg or 54 mcg qd

DRUG

placebo matching tiotropium qd

DRUG

moxifloxacin 200 mg

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim Study Coordinator · B.I. Pharma GmbH & Co. KG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2005-07-31
Completion
2005-07-31

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00257452 on ClinicalTrials.gov